WHEN TO START ANTIRETROVIRAL THERAPY IN HIV-2: THE CHALLENGE REMAINS

MARGARIDA CARDOSO, BERNARDO PIMENTEL, JOANA GRANADO, ANA CLÁUDIA MIRANDA*, TERESA BAPTISTA, SUSANA PERES, KAMAL MANSINHO.
SERVIÇO DE INFECCIOLOGIA E MEDicina TROPICAL HOSPITAL DE EGAS MONIZ CENTRO HOSPITALAR DE LISBOA OCIDENTAL – PORTUGAL

BACKGROUND

- THE PREVALENCE OF HIV-2 INFECTION IN PORTUGAL IS 3.3%.1
- HIV-2 TREATMENT IS LIMITED, FACING INTRINSIC RESISTANCE TO NNRTI AND FUSION INHIBITORS, AND DIFFERENT RESPONSE TO PROTEASE INHIBITORS. WHILE CURRENT GUIDELINES FOR HIV-1 RECOMMEND TREATMENT FOR ALL, THAT END POINT IS NOT PROPERLY DEFINED FOR HIV-2.2

MATERIALS AND METHODS

- RETROSPECTIVE OBSERVATIONAL STUDY OF A HIV-2 INFECTED PATIENTS COHORT DIAGNOSED BETWEEN 1985 AND 2017, FOLLOWED AT AN INFECTIOUS DISEASE CLINIC. STATISTICAL ANALYSIS PROCESSED BY MICROSOFT EXCEL®.

RESULTS

TOTAL PATIENTS=121

- 66%
- MEAN AGE: 58 YEARS OLD
- ORIGIN
  - 69% WEST AFRICA
  - 29% PORTUGUESE
- MEAN TIME SINCE DIAGNOSIS WAS 15 YEARS
- REASONS TO DIAGNOSIS:
  - 41% ROUTINE BLOOD SCREEN
  - 21% PREGNANCY
- TRANSMISSION ROUTE
  - 88% HETEROSEXUAL CONTACT

CURRENT ARV REGIMENS:

- NRTI BACKBONE
  - ABC/3TC
  - TDF/FTC
  - OTHERS
- PROTEINASE INHIBITORS
  - DRVr
  - LPVr
  - SQVr
  - ATVr
- INTEGRASE INHIBITORS
  - RAL
  - DTG
  - EVGc

CONCLUSIONS

- THIS COHORT REVEALED A PREDOMINANCE OF FEMALE PATIENTS, MOST ORIGINATED FROM WEST AFRICA, INFECTED BY HETEROSEXUAL TRANSMISSION.
- AFTER A MEAN TIME OF FOLLOW UP OF 15 YEARS, 29% HAVE NOT YET REQUIRED ARV THERAPY AND THOSE WHO HAVE INITIATED TREATMENT (71%), AFTER A MEAN PERIOD OF 6 YEARS, SHOWED A SIGNIFICANT IMMUNOLOGICAL IMPROVEMENT AND SUSTAINED VIROLOGIC SUPPRESSION.
- DURING THE STUDY PERIOD, THE MAJORITY OF PATIENTS (75%) MANTAIN RETENTION IN CARE, 21% WERE LOST TO FOLLOW UP AND 2% DIED (GASTROINTESTINAL DISORDER UNSPECIFIED AND SEPSIS).

- MEAN TIME UNTIL ARV THERAPY INITIATION = 6 years
- 25% started ARV therapy at diagnosis
- MEAN TCD4+ DECLINE = 31 cells/mm³ / YEAR

- 75% (n=91) ARE RETAINED IN CARE
- 21% (n=25) WERE LOST TO FOLLOW UP
- 2% (n=3) CHANGED HOSPITAL
- 2% (n=2) DIED

DURING THE STUDY PERIOD

<table>
<thead>
<tr>
<th>ARV</th>
<th>RETAINED IN CARE (N=91)</th>
</tr>
</thead>
<tbody>
<tr>
<td>YES</td>
<td>NAIVE</td>
</tr>
<tr>
<td>MEAN TIME OF FOLLOW-UP (years)</td>
<td>65 (71%)</td>
</tr>
<tr>
<td>MEAN TCD4+ COUNT (cel/mm³)</td>
<td>AT DIAGNOSIS</td>
</tr>
<tr>
<td>384</td>
<td>817</td>
</tr>
<tr>
<td>UNDETECTABLE PLasma HIV-2 RNA</td>
<td>43%</td>
</tr>
</tbody>
</table>

2 MIRANDA AC, MANSINHO K. HIV-2 INFECTION IN EUROPE, EPIDEMIOLOGY OF. IN: HOPE T., RICHMAN D., STEVENSON M. (EDS) ENCYCLOPEDIA OF AIDS. 2016. SPRINGER, NEW YORK.